LEXINGTON, Massachusetts, United States and SYDNEY, Australia – 30 October 2014 – GI Dynamics, Inc. (ASX: GID) (GI Dynamics or the Company) will hold its Special Meeting of Stockholders on Monday, November 10, 2014, at 5:00 p.m., United States Eastern Standard Time (which is 9:00 a.m. on Tuesday, November 11, 2014 Australian Eastern Daylight Time), at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111.
If not attending in person, the meeting can be accessed through conference call and webcast.
Accessing the Special Meeting of Stockholders via Webcast:
A live webcast of the call will be available on the GI Dynamics website at investor.gidynamics.com. The webcast can be directly accessed at: http://edge.media-server.com/m/p/p699ebt8/lan/en.
Accessing the Special Meeting of Stockholders via Telephone:
For those preferring to listen by telephone, please dial in five minutes prior to the start of the call and provide the passcode 38367566. Regional dial-in numbers are as follows:
- United States callers please dial toll-free 1 (888) 771-4371
- Australian callers please dial toll-free 1 800 507-265
- Other International callers please dial 1 (847) 585-4405
The webcast will be archived for 30 days following the meeting on the Company’s website at investor.gidynamics.com.
Chief Financial Officer & Company Secretary
About GI Dynamics
GI Dynamics, Inc. (ASX: GID) is the developer and marketer of EndoBarrier®, a breakthrough device that represents an entirely new class of non-surgical, non-pharmaceutical therapy for the treatment of type 2 diabetes and/or obesity. EndoBarrier is approved and commercially available in multiple countries outside the U.S. EndoBarrier is not approved for sale in the U.S. and is limited by federal law to investigational use only in the United States. GI Dynamics is conducting a pivotal clinical trial of EndoBarrier in the U.S. for the treatment of patients who have uncontrolled type 2 diabetes and are obese. Founded in 2003, GI Dynamics is headquartered in Lexington, Massachusetts. For more information, please visit www.gidynamics.com.
This announcement contains forward-looking statements concerning: our development and commercialization plans; our potential revenues, costs, profitability and financial performance; our ability to obtain reimbursement for our products; our clinical trials, and associated regulatory submissions and approvals; the number and location of commercial centres offering the EndoBarrier®; and our intellectual property position. These forward-looking statements are based on the current estimates and expectations of future events by the management of GI Dynamics, Inc. as of the date of this announcement and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks associated with the possibility that clinical trials will not be successful or confirm earlier results; risks associated with obtaining funding from third parties; risks relating to the timing and costs of clinical trials, results of clinical trials, the timing of regulatory submissions, the timing and receipt of regulatory approvals, the timing and amount of other expenses; execution risks; competition; risks related to market acceptance of products; intellectual property risks; and assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches, future financial results and other factors. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.
GI Dynamics, Inc.
Robert Crane, Chief Financial Officer
David Allen or John Granger, Hawkesbury Partners Pty Limited
+61 2 9325 9046
Dan Budwick, Pure Communications Inc.
Angela Ceberano, Flourish PR
+61 3 9092 8445